Guliz Ozgun

Vancouver, BC V5Z4E6, Canada

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 15 publications

Chrono-immunotherapy in genitourinary oncology: From emerging evidence to clinical translation (Review).

Chrono-immunotherapy in genitourinary oncology: From emerging evidence to clinical translation (Review).

Journal: Oncology letters

Published: January 07, 2026

The Prognostic Role of Inflammation on Hepatocellular Carcinoma.

The Prognostic Role of Inflammation on Hepatocellular Carcinoma.

Journal: Cancer diagnosis & prognosis

Published: December 22, 2025

Bladder Preservation in Muscle-Invasive Bladder Cancer: A Population-Based Analysis from British Columbia.

Bladder Preservation in Muscle-Invasive Bladder Cancer: A Population-Based Analysis from British Columbia.

Journal: Current oncology (Toronto, Ont.)

Published: October 26, 2025

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Prospective multicenter study of ctDNA versus tumor tissue guiding FGFR-targeted therapy in metastatic urothelial cancer.

Journal: Nature communications

Published: October 09, 2025

Machine Learning Model Integrating Computed Tomography Image-Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer.

Machine Learning Model Integrating Computed Tomography Image-Derived Radiomics and Circulating miRNAs to Predict Residual Teratoma in Metastatic Nonseminoma Testicular Cancer.

Journal: JCO clinical cancer informatics

Published: August 25, 2025

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

A simple plan: chemotherapy-sparing approaches to early-stage and regional seminoma and nonseminoma.

Journal: Annals of oncology : official journal of the European Society for Medical Oncology

Published: June 30, 2025

Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.

Author Correction: Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.

Journal: Scientific reports

Published: April 28, 2025

ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer.

ERBB2/HER2 Alterations in ctDNA and Metachronous Tissues of Patients with Metastatic Urothelial Cancer.

Journal: Clinical cancer research : an official journal of the American Association for Cancer Research

Published: November 21, 2024

Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumors.

Matching plasma and tissue miRNA expression analysis to detect viable ovarian germ cell tumors.

Journal: PloS one

Published: October 10, 2024

Once Upon a Time…. Simple, Sensible Management of Venous Access for Chemotherapy Delivery in Germ Cell Tumors.

Once Upon a Time…. Simple, Sensible Management of Venous Access for Chemotherapy Delivery in Germ Cell Tumors.

Journal: JCO oncology practice

Published: January 26, 2024

Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.

Circulating microRNA-155-3p levels predicts response to first line immunotherapy in patients with metastatic renal cell carcinoma.

Journal: Scientific reports

Published: November 28, 2023

Primary Mediastinal Germ Cell Tumors: A Thorough Literature Review.

Primary Mediastinal Germ Cell Tumors: A Thorough Literature Review.

Journal: Biomedicines

Published: December 29, 2022

Showing 1-12 of 15

Last Updated: 09/26/2026